OS Therapies initiated with a Buy at EF Hutton

EF Hutton initiated coverage of OS Therapies with a Buy rating and $21 price target. OS uses a modified listeria bacteria to target HERII-expressing cancer cells, the analyst tells investors in a research note. The firm views the initial indication of ultra-orphan osteosarcoma as a “leapfrog strategy” for changing how HERII cancers are treated.